ESTRO 2024 - Abstract Book

S497

Clinical - Breast

ESTRO 2024

95% of the prescription dose at 97.14% of the average volume (95.44-98.23%). Heart: average dose 0.53Gy (0.17 1.23Gy), V1,5Gy at 7.76%. Re-irradiated breast: average dose 13.25Gy (9.56-17.02Gy). Ipsilateral lung: V8 at 5.09% (0.64-9.55%).

One of left breast plans with present bed in red and previous in blue:

Average follow-up 9.25 months (2-28 months). Three cases more than a year. Tumor control in all patients. Acute toxicity grade 0-1 in all cases, chronic in one case.

Conclusion:

Reirradiation using APBI with external beam radiotherapy is safe, effective and efficient in selected cases, also avoiding drawbacks of other techniques. More cases and follow-up will be necessary.

Keywords: apbi, reirradiation, external

References:

Meattini, I; Marrzza, L; Saieva; C; Desideri, I; Scotti, V; Simontacchi, G; Bonomo, P; Greto, D; Monagino, M; Scoccianti, S; Lucidi, S; Paoletti, L; Bianchi, S; Pallota, S; Livi, L. Accelerated partial-Breast Irradiation Compared With Whole Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. J Clin Oncol 38. 2020. https://doi.org/10.1200/JCO.20.00560

Goldberg, M; Whelan, TJ. Accelerated Partial Breast Irradiation (APBI): Where Are We Now? Current Breast Cancer Reports (2020) 12:275-284. https://doi.org/10.1007/s12609-020-00384-x